We evaluated whether the cytokine environment, even at advanced stages of cancer, could influence the percentages of CD4+ T-lymphocyte subpopulations, in particular Th1 (CD4+ T-bet+), Th2 (CD4+ CRTH2+), Th17 (CD4+ RORγ+ cells), and Treg (CD4+CD25+CD127-) subpopulations. The gene discussed is CD4; the disease is cancer.